Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
about
Maltose-binding protein fusion allows for high level bacterial expression and purification of bioactive mammalian cytokine derivativesCurrent status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastasesDownregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling.A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivoA fusion cytokine coupling GMCSF to IL9 induces heterologous receptor clustering and STAT1 hyperactivation through JAK2 promiscuity.A MCP1 fusokine with CCR2-specific tumoricidal activityFusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactionsGIFT4 fusokine converts leukemic B cells into immune helper cellsReprogramming of B cells into regulatory cells with engineered fusokinesConcise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders.Behaviour of four different B16 murine melanoma cell sublines: C57BL/6J skin.Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell responseAnti-colorectal cancer effect of interleukin-2 and interferon-β fusion gene driven by carcinoembryonic antigen promoter.Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.
P2860
Q28542860-E30FA21C-2AA0-4484-8AD4-A1CBEC0C5985Q30412300-9ED4438F-EF1C-4D38-8A8F-5BD6050D5105Q33713800-2F8DA987-163D-427F-A93F-0F87CADF8810Q33839267-076DD69C-17FE-40C7-AC96-4CD0B1B12489Q34025058-DF331E70-93F8-4510-9300-BDC48E9B1499Q34809355-4EEEDBF4-63F4-4A12-84CC-0A3ADCB0B3DCQ35299025-4B8A3211-1B2E-4A55-AAD1-5D221F0F8804Q36550399-E4927079-7866-4C78-92DF-5E139535E809Q36842259-D65E8AA4-5708-480B-885A-AE9B83D8C841Q37066073-69AF0F0E-1800-454B-A55D-B12720BEBEDAQ38267711-D9FB9AED-BFA1-421F-AB2E-3AA47DF7C6E1Q38911551-1099C209-44B9-4072-A406-1C4898716CCEQ42543764-82DDB2E0-6E28-41A9-9B67-9037DE27DB0CQ42574280-4AD85504-265B-4922-9366-44B6A7836C0AQ47775690-F0F2EECD-754E-434E-A152-2F3CE3ED4643
P2860
Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Granulocyte-macrophage colony- ...... for cancer gene immunotherapy.
@ast
Granulocyte-macrophage colony- ...... for cancer gene immunotherapy.
@en
type
label
Granulocyte-macrophage colony- ...... for cancer gene immunotherapy.
@ast
Granulocyte-macrophage colony- ...... for cancer gene immunotherapy.
@en
prefLabel
Granulocyte-macrophage colony- ...... for cancer gene immunotherapy.
@ast
Granulocyte-macrophage colony- ...... for cancer gene immunotherapy.
@en
P2093
P1433
P1476
Granulocyte-macrophage colony- ...... for cancer gene immunotherapy.
@en
P2093
Jacques Galipeau
Jian Hui Wu
John Stagg
Nathaniel Bouganim
P304
P356
10.1158/0008-5472.CAN-04-1776
P407
P577
2004-12-01T00:00:00Z